Table 1.
PD Subjectsa |
||
---|---|---|
N | Mean (SD) | |
Age (years) | 5 | 64 (5) |
Time Since Diagnosis (years) | 5 | 8 (5) |
UPDRS Part III Score | 5 | 20 (5) |
N | Percentage | |
Male Sex | 5 | 100 |
Caucasian Race | 5 | 100 |
Anti-Parkinsonian Therapy: | ||
Carbidopa-Levodopa 25-100 mgb | 3 | 60 |
Carbidopa-Levodopa 50-200 mg | 1 | 20 |
Carbidopa-Levodopa 23-95 mg | 1 | 20 |
Demographic data taken from subjects at the time of enrollment
Subject 2001 began anti-parkinsonian therapy on month 8